Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Jennifer A. Foltz(Washington University in St. Louis), Todd A. Fehniger(Washington University in St. Louis)
Cited by 0
Related Papers
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
|Immunity|2007|988
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Cytokine activation induces human memory-like NK cells
|Blood|2012|662